Oncology and Immuno-Oncology INSIGHTS

Webinar Q&A — Advanced Toolkit for Syngeneic Tumor Modeling in Mice

photo from Webinar Q&A — Advanced Toolkit for Syngeneic Tumor Modeling in Mice

Did you miss Dr. Philip Dubé's recent webinar, Advanced Toolkit for Syngeneic Tumor Modeling in Mice? His presentation introduced advanced concepts and critical considerations for studying immuno-oncology mechanisms and therapeutics in mice. Webinar Synopsis: Syngeneic models are becoming more advanced due to the availability of genetically engineered mouse models. This advanced toolkit makes it possible to study the many intricate mechanisms through which the immune system controls...  Read More

Novel Humanized Mouse Model Mirrors Patient Responses to Immunotherapy

photo from Novel Humanized Mouse Model Mirrors Patient Responses to Immunotherapy

For the first time, a team of scientists reproduced clinical responses to adoptive T-cell transfer in a rodent model of metastatic melanoma. This could support more accurate preclinical evaluation of novel immunotherapy agents. As described in Nature Communications, University of Gothenburg researchers leveraged the super-immunodeficient CIEA NOG mouse® to establish metastatic melanoma patient-derived xenografts (PDX) for subsequent autologous adoptive cell therapy (ACT). The researchers report tumor eradication...  Read More

Humanized Mice in Cancer Bone Metastasis Studies

photo from Humanized Mice in Cancer Bone Metastasis Studies

Despite recent advances in cancer research and drug development, bone metastases remain incurable. Some of the most common cancers, such as breast, prostate, lung, and multiple myeloma frequently metastasize to bone1,2,3. As bone metastasis is difficult to treat and target, and because the bone itself is noted to induce drug resistance, the preclinical evaluation of new therapies in more translatable bone metastasis models may increase the likelihood...  Read More

Considerations for Rodent Irradiation

photo from Considerations for Rodent Irradiation

Rodent irradiation is an important tool in immunology and oncology rodent studies and has been critical in learning about tumor biology, transplant biology and immune system function. Understanding the biophysical and biological factors involved in irradiation studies is critical for optimizing model performance and improving experimental results. Irradiation preferentially kills rapidly dividing cells, including bone marrow and epithelial cells of the gut and other organs. The most...  Read More

Efficacy Studies in Humanized Mice from AACR 2017

photo from Efficacy Studies in Humanized Mice from AACR 2017

Mice engrafted with a human immune system — HIS or humanized mice — have secured important roles as efficacy models in the immuno-oncology therapeutic development pipeline. Several impressive examples of efficacy studies in humanized mice were on display at the 2017 American Association for Cancer Research (AACR) meeting. Efficacy Studies in Humanized Mice at AACR 2017 Upon engraftment of human peripheral blood mononuclear cells (PBMCs), super-immunodeficient models,...  Read More

Ali Zahalka Wins AACR 2017 Travel Award

photo from Ali Zahalka Wins AACR 2017 Travel Award

For his work investigating mechanisms connecting SNS-mediated microenvironmental effects to prostate cancer progression, Ali Zahalka was awarded Taconic Biosciences' American Association for Cancer Research (AACR) 2017 Annual Meeting Travel Award. "Our lab is interested in identifying factors that promote early-stage cancer progression," Ali told Taconic, "with the aim of developing novel therapeutic interventions." Taconic's 2017 AACR Travel Grant Winner An MD/PhD candidate in the lab of Dr....  Read More

Syngeneic Tumor Model Health Standards

photo from Syngeneic Tumor Model Health Standards

The growth in immuno-oncology research, in which the body's own immune system is recruited to fight a tumor, has prompted a shift in preclinical animal models used for oncology research. While traditional cell line xenografts in immunodeficient models are still widely used, they are generally not appropriate for immuno-oncology studies as they lack critical immune cell types required for immunotherapy efficacy. Immuno-oncology researchers have turned to two...  Read More

Modeling NK Cells in Immuno-Oncology

photo from Modeling NK Cells in Immuno-Oncology

What do Rituximab, Trastuzumab, and numerous other cancer immunotherapies have in common? Their anti-tumor efficacy involves the potent tumor-killing activity of natural killer (NK) cells. The induction of antibody-dependent cellular cytotoxicity (ADCC) in NK cells forms the basis for many important ongoing clinical efforts. These efforts are being aided by humanized immune system (HIS) rodent models, which offer an improved in vivo system for translating therapies to...  Read More

Genetically Engineered Models in Drug Development

photo from Genetically Engineered Models in Drug Development

Why do 90% of compounds fail the FDA approval process after entering Phase I clinical trials?1 Many failed projects can be traced to unreliable preclinical assessments of toxicity and efficacy of the potential new drugs2 – often due to a lack of predictive and reliable in vivo testing. Wild-type mice and rats were the gold standard in the assessment of efficacy and toxicity for many years, due...  Read More

World Cancer Day 2017

photo from World Cancer Day 2017

Cancer kills 8.2 million people every year, 4 million of whom die prematurely. Advancing the state of cancer research to prevent or mitigate this suffering is a worthy challenge for the global biosciences community. February 4 is World Cancer Day, dedicated to "awareness and education about the disease, pressing governments and individuals across the world to take action". Today, we want to recognize the contributions of those...  Read More

Close

Welcome! Tell us a little about yourself